Drug Information

Drug General Information
Drug ID
D04DYC
Former ID
DIB001112
Drug Name
PF-06463922
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1/2 [524494], [542499]
Company
Pfizer
Structure
Download
2D MOL

3D MOL
Formula
C22H20FN7O2
InChI
InChI=1S/C22H20FN7O2/c1-11-7-26-22-28-17-10-29(3)21(31)14-5-4-13(23)6-15(14)12(2)32-20-19(24)25-8-16(27-20)18(17)30(22)9-11/h4-9,12H,10H2,1-3H3,(H2,24,25)/t12-/m1/s1
InChIKey
WNAMTDCFIFUIGH-GFCCVEGCSA-N
PubChem Compound ID
75124300
PubChem Substance ID
187051779, 240227891
Target and Pathway
Target(s) ALK tyrosine kinase receptor Target Info Inhibitor [533279]
KEGG Pathway Non-small cell lung cancer
WikiPathways Differentiation Pathway
References
Ref 524494ClinicalTrials.gov (NCT01970865) A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations. U.S. National Institutes of Health.
Ref 542499(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7476).
Ref 533279PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.